Azzopardi, L., Thompson, S. A. J., Harding, Katharine, Cossburn, M., Robertson, Neil  ORCID: https://orcid.org/0000-0002-5409-4909, Compston, A., Coles, A. J. and Jones, J. L.
2014.
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
Journal of Neurology, Neurosurgery & Psychiatry
85
(7)
, pp. 795-98.
10.1136/jnnp-2013-307042
|
Abstract
Objective We have previously shown that autoimmunity following alemtuzumab treatment of multiple sclerosis can be predicted by high baseline serum interleukin IL-21 (IL-21), as measured using a now ‘redundant’ enzyme linked immunosorbent assay (ELISA). Here we ask whether currently available ELISAs have similar prognostic value. Design Serum IL-21 from 141 individuals with relapsing remitting multiple sclerosis was measured using the now ‘redundant’ IL-21 ELISA and five further currently available kits. All patients had been treated with alemtuzumab; 61/141 had developed secondary autoimmunity. Results The ‘redundant kit’, and one current kit, confirmed higher baseline serum IL-21 in patients with autoimmunity (542 pg/mL vs. 222 pg/mL and 53.1 pg/mL vs. 9.3 pg/mL respectively) and showed positive correlation. However, only the ‘redundant’ kit had predictive utility. Conclusions Currently available IL-21 ELISA kits should not be used to counsel individuals with multiple sclerosis considering treatment with alemtuzumab.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Schools: | Research Institutes & Centres > MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) Schools > Medicine |
| Subjects: | R Medicine > R Medicine (General) |
| Publisher: | BMJ Publishing Group |
| ISSN: | 0022-3050 |
| Last Modified: | 28 Oct 2022 09:45 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/75624 |
Citation Data
Cited 43 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Altmetric
Altmetric